✨ Unlock Data Exports And Disclosure Access. Start Your 30-Day Free Trial Today →

Ascendis Pharma A/S

Common Name
Ascendis Pharma
Country
Denmark
Sector
Healthcare
Industry
Biotechnology
Employees
1,017
Ticker
ASND
Exchange
NASDAQ/NGS
Description
Ascendis Pharma A/S is a biopharmaceutical company that focuses on developing innovative drug therapies for unmet medical needs. The company employs its proprietary TransCon technology platform to cre...

Ascendis Pharma's GHG Emissions Data Preview

In 2024, Ascendis Pharma completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources) and Scope 2 (indirect emissions from purchased energy).

However, Ascendis Pharma has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.

Metric (tCO2e)202420232022
2021 - 2017
Total Scope 1
0000000
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Total Scope 2
Market-Based
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
0000000
Location-Based
Copy/Paste is a PRO feature.
a
0000000
Copy/Paste is a PRO feature.
0000000
Total Scope 3
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
0000000
Total Scope 1 Revenue Intensity (tCO2e/$M)
0000000
Copy/Paste is a PRO feature.
Copy/Paste is a PRO feature.
0000000
Limited Data Preview
You are viewing a limited preview of Ascendis Pharma’s GHG emissions dataset. The full dataset, available for download, includes Scope 1, 2, and 3 emissions with detailed category-level breakdowns, historical coverage back to 2024, and revenue-based intensity metrics for each scope.
Access Datasets, Disclosures, and Sources
pro
Remove manual data sourcing from your workflow. Subscribe to Tracenable Pro to get credits for accessing and exporting datasets and disclosures across 8,500+ companies with 10+ years of historical coverage.
Download granular datasets (CSV/XLS)
Access underlying corporate disclosures (PDF)
Trace all values back to their original sources
Formats Included
Excel
CSV
Json
All data fully traceable to original sources
Used by 1,000+ teams in finance, climate, and research
Access this data via API
$curl "https://tracenable.com/api/v1/ghg-emissions/absolute?ticker=ASND&reporting_period=2024"

Verified Sources Behind Ascendis Pharma’s Greenhouse Gas (GHG) Emissions Data

Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Ascendis Pharma’s data sources below and access millions more through our Disclosure Search.

a. Ascendis Pharma's ESG Report 2024

Insights into Ascendis Pharma's Operational Emissions

In 2024, the total operational greenhouse gas (GHG) emissions of Ascendis Pharma amounted to 1,109 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).a

Ascendis Pharma's Scope 1 Emissions Over Time

2024020406080tCO2e
  • Total Scope 1
  • Year-over-Year Change

What are Ascendis Pharma's Scope 1 emissions?

In 2024, the total Scope 1 emissions of Ascendis Pharma were 62 metric tons of CO₂ equivalent (tCO₂e).a

What are Ascendis Pharma's Scope 2 emissions?

In 2024, Ascendis Pharma reported Scope 2 greenhouse gas (GHG) emissions of 672 tCO₂e using the market-based method and 1,047 tCO₂e using the location-based method.a

What methodology does Ascendis Pharma use for Scope 2 reporting?

In 2024, Ascendis Pharma reported its Scope 2 emissions using the market-based method and using the location-based method.a

Ascendis Pharma's Scope 2 Emissions Over Time

202403006009001.2 ktCO2e
  • Total Scope 2 Location-Based
  • Total Scope 2 Market-Based

Insights into Ascendis Pharma’s GHG Emissions Intensity Compared to Industry Peers

In 2024, Ascendis Pharma reported Scope 1 greenhouse gas (GHG) emissions of 62 tCO₂e and total revenues of USD 443 millions. This translates into an emissions intensity of 0.14 tCO₂e per millions USD.a

Ascendis Pharma's Scope 1 Emissions Intensity Compared to Peers

2505005,000100,000Scope 1 Emissions (tCO2e)5202001,0005,000Revenues (Millions of USD)ICGenmabYear: 2024Scope 1: 534 tCO2eRevenue: $M 3,003Scope 1 Intensity: 0.18 tCO2e/$MInnoCare PharmaYear: 2023Scope 1: 20 tCO2eRevenue: $M 104Scope 1 Intensity: 0.19 tCO2e/$MBio-TechneYear: 2023Scope 1: 3,001 tCO2eRevenue: $M 1,137Scope 1 Intensity: 2.64 tCO2e/$MShanghai Henlius BiotechYear: 2023Scope 1: 6,909 tCO2eRevenue: $M 830Scope 1 Intensity: 8.32 tCO2e/$MRemeGenYear: 2024Scope 1: 54 tCO2eRevenue: $M 234Scope 1 Intensity: 0.23 tCO2e/$MIdorsiaYear: 2024Scope 1: 733 tCO2eRevenue: $M 124Scope 1 Intensity: 5.90 tCO2e/$MInsmedYear: 2024Scope 1: 1,666 tCO2eRevenue: $M 364Scope 1 Intensity: 4.58 tCO2e/$MBB BiotechYear: 2024Scope 1: 12 tCO2eRevenue: $M 91Scope 1 Intensity: 0.13 tCO2e/$MShanghai Junshi BiosciencesYear: 2024Scope 1: 5,308 tCO2eRevenue: $M 267Scope 1 Intensity: 19.88 tCO2e/$MBavarian NordicYear: 2024Scope 1: 4,111 tCO2eRevenue: $M 797Scope 1 Intensity: 5.16 tCO2e/$MALK-AbelloYear: 2023Scope 1: 10,256 tCO2eRevenue: $M 714Scope 1 Intensity: 14.36 tCO2e/$MAkesoYear: 2024Scope 1: 6,408 tCO2eRevenue: $M 318Scope 1 Intensity: 20.17 tCO2e/$MSK BiopharmaceuticalsYear: 2024Scope 1: 414 tCO2eRevenue: $M 373Scope 1 Intensity: 1.11 tCO2e/$MSK BioscienceYear: 2023Scope 1: 5,863 tCO2eRevenue: $M 289Scope 1 Intensity: 20.28 tCO2e/$MZai LabYear: 2023Scope 1: 15 tCO2eRevenue: $M 267Scope 1 Intensity: 0.06 tCO2e/$MGubraYear: 2024Scope 1: 8 tCO2eRevenue: $M 37Scope 1 Intensity: 0.22 tCO2e/$MCytokineticsYear: 2024Scope 1: 242 tCO2eRevenue: $M 18Scope 1 Intensity: 13.10 tCO2e/$MIIInventivaYear: 2024Scope 1: 554 tCO2eRevenue: $M 10Scope 1 Intensity: 57.88 tCO2e/$MAlnylam PharmaceuticalsYear: 2024Scope 1: 3,832 tCO2eRevenue: $M 2,248Scope 1 Intensity: 1.70 tCO2e/$MPharmaron BeijingYear: 2024Scope 1: 34,268 tCO2eRevenue: $M 1,682Scope 1 Intensity: 20.37 tCO2e/$MAsymchem Laboratories (Tianjin)Year: 2024Scope 1: 31,787 tCO2eRevenue: $M 795Scope 1 Intensity: 39.96 tCO2e/$MCCCatalyst PharmaceuticalsYear: 2024Scope 1: 4 tCO2eRevenue: $M 493Scope 1 Intensity: 0.01 tCO2e/$MZealand PharmaYear: 2024Scope 1: 145 tCO2eRevenue: $M 9Scope 1 Intensity: 16.60 tCO2e/$MAscendis PharmaYear: 2024Scope 1: 62 tCO2eRevenue: $M 443Scope 1 Intensity: 0.14 tCO2e/$M

How does Ascendis Pharma's GHG emissions intensity compare to its peers?

In 2024, Ascendis Pharma reported a Scope 1 emissions intensity of 0.14 tCO₂e per millions USD. Compared to the peer group median of 5.16, this places the company below its industry benchmark, indicating it is more carbon-efficient than most competitors.a

Where does Ascendis Pharma rank on GHG emissions intensity within its industry?

In 2024, Ascendis Pharma ranked 4 out of 23 companies in its industry peer group, based on Scope 1 emissions intensity (measured in tCO₂e per millions USD).a

This places Ascendis Pharma among the top performers, with one of the lowest emissions intensities relative to peers.a

Want Full Access to Ascendis Pharma's GHG Emissions Dataset?
Start 30-Day Free Trial